675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Announces Second Quarter 2026 Operating Results and Provides Business Update
Material Contracts, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Reg. FD, Other Events
2026 Stock Incentive Plan Approved by Spero Therapeutics Stockholders
Utebzi approved in the US for adults with complicated urinary tract infections (cUTIs)
Announces First Quarter 2026 Operating Results and Provides Business Update
Annual Report to Security Holders
Financial Results, Press Release
Material disclosure
Q2
Q1
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence
Confidential Treatment Order